## PEER-REVIEW REPORT

**Name of journal:** World Journal of Nephrology  
**Manuscript NO:** 67699  
**Title:** Renoprotective Role of Amlodipine in Patients with Hypertensive Chronic Kidney Disease  

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 03971255  
**Position:** Peer Reviewer  
**Academic degree:** PhD  
**Professional title:** Doctor, Professor  
**Reviewer’s Country/Territory:** China  
**Author’s Country/Territory:** India  
**Manuscript submission date:** 2021-05-28  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2021-05-29 01:07  
**Reviewer performed review:** 2021-06-07 05:14  
**Review time:** 9 Days and 4 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
In this manuscript, author sought to investigate the “Renoprotective Role of Amlodipine in Patients with Hypertensive Chronic Kidney Disease”. This manuscript is an interesting study. However, some points should be concerned in this study. 1. “The age-standardized global prevalence of CKD was higher in women and girls (9.5%) than in men and boys (7.3%) and nearly one-third of CKD cases were in China (132.3 million) and India (115.1 million).” “The prevalence of CKD in India is limited, and since the eGFR estimating equation and the Modification of Diet in Renal Disease formula have not been validated.” These two sentences seem to be inconsistent, in which, the prevalence of CKD in India is limited, what is the specific meaning of the message? 2. Pay attention to the formatting issues of the manuscript, e.g., lines 147-158 on page 4. 3. The content of “Blood Pressure Control in CKD” is too little, so it is suggested that the author narrate it from many aspects. 4. The article has mentioned many times the single action and synergistic drug use, can we simply expand it? 5. The article mentions “Emergent Role of CCBs in Patients with HTN and CKD”, and the authors may consider adding the description of DHP-CCBs. 6. The authors suggest that “amlodipine - the only CCB” is not a rigorous statement. 7. More detailed description of the Accomplish Trial, Sakura Trial, and ASCOT-BPLA Trial is recommended. 8. It is suggested that the author should make a proper outlook in the conclusion.